About 40 percent of chronic migraine sufferers taking an experimental drug developed by Novartis and Amgen saw the number of days they suffered a migraine cut by at least half, beating the placebo in the trial.
The latest analysis from the mid-phase study amounted to a "statistically significant reduction in monthly migraine days", Novartis said about the experimental AMG 334 compound.
Novartis has struck pacts with its U.S.-based rival Amgen to develop migraine and Alzheimer's treatments as it seeks to bolster its neuroscience portfolio.
The latest analysis from the mid-phase study amounted to a "statistically significant reduction in monthly migraine days", Novartis said about the experimental AMG 334 compound.
Novartis has struck pacts with its U.S.-based rival Amgen to develop migraine and Alzheimer's treatments as it seeks to bolster its neuroscience portfolio.
